ITA Senior Scientist Jagpreet Chhatwal, PhD serves and as the senior and corresponding author of a paper based on a study on the benefits of directly-acting generic drugs available in India in treating hepatitis C virus (HCV). The study found the use of such drugs increased lifespan while reducing lifetime health care costs. 

"Our hypothesis was that treatment would be cost saving, given the low drug costs in India. However, we were pleasantly surprised to find that the full payback was achieved so soon after treatment," said Chhatwal, who also serves as Assistant Professor of Radiology at Harvard Medical School.

To read the entire article, visit